Lo studio nazionale finlandese per facilitare l'accesso dei pazienti a farmaci antitumorali mirati (FINPROVE)
Lo studio nazionale finlandese per facilitare l'accesso dei pazienti a farmaci antitumorali mirati per determinare l'efficacia nel trattamento dei tumori avanzati con un profilo molecolare noto
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Tanja Juslin
- Numero di telefono: +358405597415
- Email: tanja.juslin@hus.fi
Luoghi di studio
-
-
-
Kuopio, Finlandia
- Reclutamento
- Kuopio University Hospital
-
Contatto:
- Okko Kääriäinen, MD
-
Oulu, Finlandia
- Reclutamento
- Oulu University Hospital OYS Cancer Center
-
Contatto:
- Sanna Iivanainen, MD. PhD.
-
Tampere, Finlandia
- Reclutamento
- Tampere University Hospital Department of Oncology
-
Contatto:
- Minna Tanner, MD, PhD
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlandia
- Reclutamento
- Turku University Hospital Cancer Centre
-
Contatto:
- Erika Alanne, MD, PhD
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlandia, 00029
- Reclutamento
- Helsinki University Hospital Comprehensive Cancer Center
-
Contatto:
- Tanja Juslin
-
Investigatore principale:
- Katriina Jalkanen, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
-
ECOG performance status 0-2
-
Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:
- Absolute neutrophil count ≥ 1.5 x 109/l
- Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
- Platelets > 75 x 109/l (not applicable for hematological patients)
- Total bilirubin < 1.5 x ULN
- AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
-
Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.
-
Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.
-
Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.
-
A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.
-
Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.
Exclusion Criteria:
-
Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.
-
Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:
- Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
- Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
-
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
-
Patient is pregnant or nursing.
-
Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible
-
Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible
-
Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Alectinib
For patients with a molecular tumor profile that can potentially be targeted by alectinib. |
ALK
Altri nomi:
|
|
Sperimentale: Cobimetinib
For patients with a molecular tumor profile that can potentially be targeted by cobimetinib. |
MEK1, MEK2
Altri nomi:
|
|
Sperimentale: Vismodegib
For patients with a molecular tumor profile that can potentially be targeted by vismodegib. |
Hedgehog
Altri nomi:
|
|
Sperimentale: Trastuzumab+Pertuzumab
For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination. |
HER2
Altri nomi:
|
|
Sperimentale: Entrectinib
For patients with a molecular tumor profile that can potentially be targeted by entrectinib. |
NTRK/ ROS1, ALK
Altri nomi:
|
|
Sperimentale: Atezolizumab
For patients with a molecular tumor profile that can potentially be targeted by atezolizumab. |
PD-L1
Altri nomi:
|
|
Sperimentale: Vemurafenib
For patients with a molecular tumor profile that can potentially be targeted by vemurafenib. |
BRAF V600
Altri nomi:
|
|
Sperimentale: Regorafenib
For patients with a molecular tumor profile that can potentially be targeted by regorafenib. |
KIT/BRAF, RET
Altri nomi:
|
|
Sperimentale: Apalutamide
For patients with a molecular tumor profile that can potentially be targeted by apalutamide. |
AR
Altri nomi:
|
|
Sperimentale: Abemaciclib
For patients with a molecular tumor profile that can potentially be targeted by abemaciclib. |
CDK4/6
Altri nomi:
|
|
Sperimentale: Tepotinib
For patients with a molecular tumor profile that can potentially be targeted by tepotinib. |
MET ex14
Altri nomi:
|
|
Sperimentale: Dabrafenib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib. |
RAF
Altri nomi:
|
|
Sperimentale: Trametinib
For patients with a molecular tumor profile that can potentially be targeted by trametinib. |
MEK1, MEK2
Altri nomi:
|
|
Sperimentale: Dabrafenib+Trametinib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination. |
RAF, MEK1, MEK2
Altri nomi:
|
|
Sperimentale: Pemigatinib
For patients with a molecular tumor profile that can potentially be targeted by pemigatinib. |
FGFR2
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease control rate
Lasso di tempo: 16 weeks
|
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD) |
16 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Duration of treatment
Lasso di tempo: 5 years
|
Time on drug |
5 years
|
|
Adverse Events
Lasso di tempo: 5 years
|
Treatment-related grade ≥3 and serious adverse events |
5 years
|
|
Overall response
Lasso di tempo: 5 years
|
Best overall response (defined as patients by CR, PR, SD) |
5 years
|
|
PFS
Lasso di tempo: 5 years
|
Progression free survival |
5 years
|
|
OS
Lasso di tempo: 5 years
|
Overall survival |
5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie ematologiche
- Malattie emiche e linfatiche
- Neoplasie ematologiche
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Amides
- Indoli
- Sulfonamidi
- Solfoni
- Vemurafenib
- Abemaciclib
- Dabrafenib
- trametinib
- atezolizumab
- cobimetinib
- Regorafenib
- entrectinib
- Pemigatinib
- alectinib
- apalutamide
- Hhantag691
- tepotinib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- FINPROVE
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Investigators plan to share the clinical study report.
Periodo di condivisione IPD
2026-2027
Criteri di accesso alla condivisione IPD
Will be made available through European regulatory CTIS programme.
Tipo di informazioni di supporto alla condivisione IPD
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .